Melanoma vaccines

Hospital Medicine

Volumn 65, Issue 11, 2004, Pages 668-673

  Elliott, Bruce ^b   Dalgleish, Angus ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CANCER TESTIS ANTIGEN; CANCER VACCINE; CANVAXIN; DNA VACCINE; GANGLIOSIDE ANTIGEN; HEAT SHOCK PROTEIN; M VAX; MELACINE; MELANOMA ANTIGEN 1; MELANOMA VACCINE; PEPTIDE ANTIGEN; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENICITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE TARGETING; HUMAN; IMMUNOGENICITY; MELANOMA; REVIEW;

EID: 9344234988     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.11.17046     Document Type: Review

References (20)

1. Barth A, Hoon DS, Foshag LJ et al (1994) Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54(13): 3342-5
2. Berd D, Maguire HC Jr, Schuchter LM et al (1997) Autologous hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15(6): 2359-70
3. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF (2001) Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7(7): 1837-8
4. Castelli C, Ciupitu AM, Rini F et al (2001) Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61(1): 222-7
5. Czarnetzki BM, Macher E, Sucio S, Thomas D, Steerenberg PA, Rumke P (1993) Longterm adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 29A(9): 1237-42
6. Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90(8): 3539-43
7. Hersey P, Coates AS, McCarthy WH et al (2002) Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20(20): 4181-90
8. Hsueh EC, Gupta RK, Qi K, Morton DL (1998) Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16(9): 2913-20
9. Hsueh EC, Gupta RK, Foshag LJ et al (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20(23): 4549-54
10. Kirkwood JM, Ibrahim J, Sosman JA et al (2001) High-dose interferon alfa-2b significantly prolonged relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9): 2370-80
11. Mitchell MS, von Eschen KB (1997) Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 16: 494a
12. Morton DL, Foshag LJ, Hoon DS et al (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216(4): 463-82
13. Morton DL, Hsueh EC, Essner R et al (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236(4): 438-48
14. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3): 328-32
15. Plummer M, Franceschi S (2002) Strategies for HPV prevention. Virus Res 89: 28-93
16. Schaed SG, Houghton AN, Klimek VM et al (2000) Immunization of melanoma patients with both tyrosinase (370D) and GP100 (210M) peptides: Comparison of adjuvants and peptide immunogenicity. Proc Am Assoc Cancer Res 41: 4029
17. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21(21): 4016-26
18. Sondak VK, Liu PY, Tuthill RJ et al (2002) Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20(8): 2058-66
19. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11): 1669-78
20. Wallack MK, Sivanandham M, Balch CM et al (1998) Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysates trial. J Am Coll Surg 187(1): 69-77